Disruption of the PI3K/AKT/mTOR pathway in the brains of AD patients, which is associated with disease severity [20,21], underscores the importance of balancing IGF-1R/PI3K/AKT for AD treatment. This evidence concerns the gene IGF1R and Alzheimer disease.